Current management of esophageal squamous-cell carcinoma in Japan and other countries

Gastrointestinal Cancer Research

Volumn 3, Issue 4, 2010, Pages 153-161

  Higuchi, Katsuhiko ^a   Koizumi, Wasaburo ^a   Tanabe, Satoshi ^a   Sasaki, Tohru ^a   Katada, Chikatoshi ^a   Azuma, Mizutomo ^a   Nakatani, Kento ^a   Ishido, Kenji ^a   Naruke, Akira ^a   Ryu, Takahiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; NEDAPLATIN; PACLITAXEL; VINDESINE;

ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL TRIAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGOSCOPY; EUROPE; FOLLOW UP; HUMAN; JAPAN; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NORTH AMERICA; OVERALL SURVIVAL; RADIATION DOSE; SURVIVAL RATE;

EID: 77951144091     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Parkin DM, Bray F: Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer 45:756-764, 2009
2. Blot WJ, McLaughlin JK: The changing epi demiology of esophageal cancer. Semin Oncol 26 (suppl 15):2-8, 1999
3. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053, 1998
4. Lagergren J, Bergström R, Lindgren A, et al: Symp tomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825-831, 1999
5. Lee CH, Wu DC, Lee JM, et al: Carcinogenetic impact of alcohol intake on squamous cell carci - noma risk of the oesophagus in relation to tobacco smoking. Eur J Cancer 43:1188-1199, 2007
6. Yokoyama A, Omori T: Genetic polymorphism of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Jpn J Clin Oncol 33:111-121, 2003
7. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2008. Foundation for Promotion of Cancer Research.
8. The Japanese Society of Esophageal Diseases: Comprehensive registry of esophageal cancer in Japan (1998, 1999) & Long-term result of Esophagectomy in Japan (1988-1997), 2002.
9. th ed. New York: Wiley-Liss, 2002.
10. Kuwano K, Nishimura Y, Ohtsu A, et al: Guide-lines for diagnosis and treatment of carcinoma of the esophagus. April 2007 edition: Part I. Edited by the Japan Esophageal Society. Esophagus 5:61-73, 2004
11. Katada C, Muto M, Manabe T, et al: Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc 57:165-169, 2003
12. Higuchi K, Tanabe S, Koizumi W, et al: Ex pan-sion of the indications for endoscopic mucosal resection in patients with superficial esophageal carcinoma. Endoscopy 39:36-40, 2007
13. Katada C, Muto M, Momma K, et al: Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae-a multi-center retrospective cohort study. Endoscopy 39:779-783, 2007
14. Tanabe S, Koizumi W, Higuchi K, et al: Clinical outcomes of endoscopic oblique aspiration mucosectomy for superficial esophageal cancer. Gastrointest Endosc 67:814-820, 2008
15. Oyama T, Tomori A, Hotta K, et al: Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3(suppl 1): S67-S70, 2005
16. Fujishiro M, Yahagi N, Kakushima N, et al: Endo scopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastro enterol Hepatol 4:688-694, 2006
17. Yano T, Muto M, Minashi K, et al: Photo dynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 62: 31-36, 2005
18. Nomura T, Miyashita M, Makino H, et al: Argon plasma coagulation for the treatment of superficial esophageal carcinoma. J Nippon Med Sch 74:163-167, 2007
19. Pech O, Gossner L, May A, et al: Endoscopic resection of superficial esophageal squamouscell carcinomas: Western experience. Am J Gastroenterol 99:1226-1232, 2004
20. Das A, Singh V, Fleischer DE, et al: A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol 103:1340-1345, 2008
21. Probst A, Golger D, Arnholdt H, et al: Endoscopic submucosal dissection of early cancers, flat adenomas, and submucosal tumors in the gastrointestinal tract. Clin Gastroenterol Hepatol 7:149-155, 2009
22. Shimizu Y, Kato M, Yamamoto J, et al: EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. Gastrointest Endosc 59:199-204, 2004
23. Ishikura S, Nihei K, Ohtsu A, et al: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697-2702, 2003
24. Minashi K, Muto M, Ohtsu A: Nonsurgical treatments for submucosal esophageal squamous cell carcinomas. Esophagus 4:159-164, 2007
25. Kato H, Fukuda H, Udagawa H, et al: A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG 9708). Proc Am Soc Clin Oncol 22:286, 2003 (abstr 1147)
26. Law S, Fok M, Chow S, et al: Preoperative chem otherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Car diovasc Surg 114:210-217, 1997
27. Ancona E, Ruol A, Santi S, et al: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91:2165-2174, 2001
28. Nygaard K, Hagen S, Hansen HS, et al: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16:1104-1110, 1992
29. Apinop C, Puttisak P, Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 41:391-393, 1994
30. Le Prise E, Etienne PL, Meunier B, et al: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73:1779-1784, 1994
31. Bosset JF, Gignoux M, Triboulet JP, et al: Chemo - radiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161-167, 1997
32. Lee JL, Park SI, Kim SB, et al: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for respectable esophageal squamous cell carcinoma. Ann Oncol 15:947-954, 2004
33. Gebski V, Burmeister B, Smithers BM, et al: Survival benefits from neoadjuvant chemoradio - therapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226-234, 2007
34. Ando N, Ozawa S, Kitagawa Y, et al: Im provement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232: 225-232, 2000
35. Akiyama H, Tsurumaru M, Udagawa H, et al: Radical lymph node dissection for cancer of the thoracic esophagus.AnnSurg 220:364-372, 1994
36. Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21: 4592-4596, 2003
37. Igaki H, Kato H, Ando N, et al: A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 26(suppl):215s, 2008 (abstr 4510)
38. Cooper JS, Guo MD, Herskovic A, et al: Chemo - radiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623-1627, 1999
39. Muro K, Ohtsu A, Ishikura S, et al: A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906). J Clin Oncol 25 (suppl):644s, 2007 (abstr 15137)
40. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002
41. Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ: Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 94:1059-1066, 2007
42. Stahl M, Stuschke M, Lehmann N, et al: Chemo radiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317, 2005
43. Bedenne L, Michel P, Bouché O, et al: Chemo - radiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168, 2007
44. Ohtsu A, Boku N, Muro K, et al: Definitive chemo radiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915-2921, 1999
45. Ishida K, Ando N, Yamamoto S, et al: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34:615-619, 2004
46. Ishikura S, Ohtsu A, Shirao K, et al: A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esopha geal cancer: Japan Clinical Oncology Group trial (JCOG 9908). Esophagus 2:133-137, 2005
47. Higuchi K, Koizumi W, Tanabe S, et al: A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol 87:398-404, 2008
48. Ezdinli EZ, Gelber R, Desai DV, et al: Chemo - therapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46:2149-2153, 1980
49. Kelsen DP, Bains M, Cvitkovic E, et al: Vinde-sine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 63:2019-2021, 1979
50. Engstrom PF, Lavin PT, Klaassen DJ: Phase II evaluation of mitomycin and cisplatin in ad vanced esophageal carcinoma. Cancer Treat Rep 67: 713-715, 1983
51. Taguchi T, Wakui A, Nabeya K, et al: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother 19:483-488, 1992
52. Conroy T, Etienne PL, Adenis A, et al: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastro - intestinal Treat Cancer Cooperative Group. J Clin Oncol 14:164-170, 1996
53. Muro K, Hamaguchi T, Ohtsu A, et al: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955-959, 2004
54. Tahara M, Fuse N, Kato K, et al: Weekly paclitaxel in patients with advanced or recurrent esophageal cancer (EC) previously treated with platinum-based chemotherapy: Results of phase II study. ASCO 2008 Gastrointestinal Cancers Symposium. (abstr 48)
55. Iizuka T, Kakegawa T, Ida H, et al: Phase II evaluation of combined cisplatin and vindesine in ad vanced squamous cell carcinoma of the esopha gus: Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 21:176-179, 1991
56. Iizuka T, Kakegawa T, Ide H, et al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172-176, 1992
57. Hayashi K, Ando N, Watanabe H, et al: Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31:419-423, 2001
58. Bleiberg H, Conroy T, Paillot B, et al: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216-1220, 1997
59. Ilson DH, Ajani J, Bhalla K, et al: Phase II trial of paclitaxel, fluorouracil, and cisplatin in pa tients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834, 1998
60. Ilson DH, Saltz L, Enzinger P, et al: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270-3275, 1999
61. Conroy T, Etienne PL, Adenis A, et al: Vino relbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 13: 721-729, 2002
62. Millar J, Scullin P, Morrison A, et al: Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer 93:1112-1116, 2005
63. Laack E, Andritzky B, Dürk H, et al: Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie 28:647-650, 2005
64. Lee J, Im YH, Cho EY, et al: A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 62:77-84, 2008
65. Muro K: A phase II study of Nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905). Jpn J Cancer Clin 50:269-275, 2004
66. Airoldi M, Cortesina G, Giordano C, et al: Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 20:19-24, 2003
67. Schmid EU, Alberts AS, Greeff F, et al: The value of radiotherapy or chemotherapy after intubation for advanced esophageal carcinoma-a prospective randomized trial. Radiother Oncol 28:27-30, 1993
68. Levard H, Pouliquen X, Hay JM, et al: 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 164:849-857, 1998
69. Bleiberg H, Conroy T, Paillot B, et al: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216-1220, 1997
70. Lordick F, Lorenzen S, Al-Batran S, et al: Cetuximab and cisplatin/5-FU (CF) versus CF in firstline metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 26(suppl):224s, 2008 (abstr 4546)
71. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612-1619, 2006
72. Ku GY, Shah MA, Tang LH, et al: Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer. J Clin Oncol 26(suppl):661s, 2008 (abstr 15580)
73. Safran H, Suntharalingam M, Dipetrillo T, et al: Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395, 2008
74. Bonner JA, Harari PM, Giralt J, et al: Radio therapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006